NeuroOne Medical Technologies Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $10.2M
- Price
- $1.12
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.88%
- Volume
- 63.3K
About
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Quick stats
Shares outstanding9.1M
Computed float8.6M
Float / shares94.3%
Cash runway (months)5.3
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001500198
Websitehttps://nmtc1.com
AI Summary
AI-generated1/8
standardbullishoperations update
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
NeuroOne reported preliminary fiscal Q4 2026 product revenue of $3.8 million, up 38.4% year-over-year, with full-year revenue of $10.5 million landing at the top of guidance.
In September the company secured a record $4.5 million purchase order, bringing total open purchase orders to $5.4 million through fiscal Q1 2027.
CEO Dave Rosa cited 24.2% growth in fiscal 2026 product orders and pointed to the trigeminal neuralgia system commercialization, international expansion, and drug delivery platform as upcoming growth drivers. Full audited results are expected in December 2026.
Red flags
- figures are preliminary and unaudited, subject to adjustment upon year-end audit